10times
10 Jul 2021Ended

Targeting HER2/3 in Advanced NSCLC: Where Are We and Where Are We Going

AboutSpeakersExhibitorsReviewsPhotos

Timings

09:00 AM - 06:00 PM
Not Verified

Official Links

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Jul 2021
+1 more edition

Frequency

Annual
Next edition likely in Jul 2022
Claim event to edit details

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing .. Read more medical education for physicians. The HER2 mutation has been identified as an oncogenic driver in non–small cell lung cancer (NSCLC). HER2 amplification is a mechanism of acquired resistance to first-generation tyrosine kinase inhibitors (TKIs) in EGFR mutant-positive lung cancers. Community clinicians who treat patients with HER2-altered NSCLC need to be up to date on the most accurate methods of diagnosis to effectively select frontline therapy and beyond to provide the best care to their patients. Topics include testing strategies for HER2 alterations, current and emerging treatment options for HER2 alteration-positive NSCLC and the management of adverse events relating to HER2-targeted treatment. This activity is intended for medical oncologists, pathologists, and other health care professionals interested in the latest advances in the treatment of patients with NSCLC. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with NSCLC are also invited to participate.

  • Share your Experience
  • Organizer
Logo Follow Company

Physicians Education ResourceRenowned

USA109 Total Events / 64 Upcoming Events

More Events From The Organizer

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results